NGS Panel Selection for Sarcoma
For sarcoma patients, request a targeted RNA-based NGS panel that covers all three NTRK genes (NTRK1, NTRK2, NTRK3) plus a comprehensive fusion panel detecting multiple sarcoma-associated gene rearrangements, rather than DNA-only sequencing. 1
Optimal Testing Strategy
Primary Recommendation: RNA-Based Fusion Panel
RNA-based massive parallel sequencing (MPS) is the preferred method because:
- DNA-based NGS panels are inadequate for detecting NTRK2 and NTRK3 fusions due to their large introns 1
- RNA panels systematically detect fusion transcripts and identify novel fusion partners 1
- Recent real-world data shows RNA-NGS identifies fusions in 87.5% of round cell sarcomas and enables diagnostic reclassification in 41.1% of cases 2
- A dual DNA-RNA panel detects significantly more fusion genes (20.3% vs 7.4%) and therapeutically targetable kinase fusions (3.5% vs 1.2%) compared to DNA-only testing 3
Panel Specifications
Your NGS panel should include:
- Minimum 138-265 genes covering RNA fusion transcripts 2, 1
- All three NTRK genes (NTRK1, NTRK2, NTRK3) for fusion detection 1
- Common sarcoma fusion partners: EWSR1, FUS, SS18, PAX3/7, FOXO1, ETV6, and others 4, 2
- DNA mutation analysis for TP53, CDKN2A/B, RB1, PTEN, PIK3CA, and other recurrent alterations 5, 6
When to Order Testing
Priority 1: Highest Yield Scenarios
Order RNA-based NGS immediately for:
- Locally advanced, unresectable tumors 1
- Metastatic disease failing conventional therapies 1
- Round cell sarcomas with atypical morphology (87.5% fusion detection rate) 2
- Undifferentiated sarcomas (21.1% fusion detection, 75% treatment impact when positive) 2
- Infantile fibrosarcoma (for diagnostic confirmation of ETV6-NTRK3) 1
Lower Priority
- Primary resectable sarcomas generally do not require immediate NTRK testing unless needed for definitive diagnosis 1
- However, testing may provide actionable information for high-risk patients who later relapse 1
Critical Implementation Details
Pre-Screening Strategy
Consider pan-TRK immunohistochemistry (IHC) as a fast, inexpensive pre-screening tool before RNA sequencing 1. However, be aware:
- IHC is not reliable in uterine tumors due to endogenous TRK expression 1
- Sarcomas with myogenic/neural differentiation may show focal TRK expression—only diffuse staining should be considered positive 1
- Strong TRK staining can occur with NTRK amplification (not fusion), requiring molecular confirmation 1
Exclusion Criteria to Reduce Costs
Exclude ~45% of sarcomas from NTRK testing if they have pathognomonic genetic alterations that are mutually exclusive with NTRK fusions 1:
- Other known translocations
- Kinase mutations
- MDM2/CDK4 amplification
Tissue Requirements
- Fresh frozen tissue is ideal but FFPE (formalin-fixed paraffin-embedded) tissue is acceptable 7
- RNA extraction succeeds in ~89% of FFPE samples, though fragmentation can limit quality in ~29% of cases 7
- Obtain consent for tumor banking and whole genome sequencing access where possible 8
Interpretation Pitfalls
Critical Warnings
Non-oncogenic NTRK rearrangements: RNA-based NGS may identify aberrant NTRK rearrangements that don't produce constitutively active fusion proteins—these are NOT predictive of treatment response 1
NTRK point mutations: These occur more frequently than fusions but are NOT predictive of TRK inhibitor response 1
Commercial panel variability: Different commercial RNA-NGS panels show "remarkable differences in detection rate"—choose validated platforms 1
Tumor mutational burden: Expect low TMB in sarcomas, particularly those with disease-defining fusions (94.6% have TMB <10 mut/MB) 9—don't rely on TMB for immunotherapy decisions
Clinical Utility Expectations
Realistic Outcomes
Based on recent real-world data:
- Diagnostic refinement: 41.1% of cases 2
- Treatment impact: 26.4% of patients 2
- Actionable alterations: 19.5-24% according to OncoKB 6, 5
- Clinical benefit from NGS-directed therapy: Only 4-5% of patients 9
Therapeutic Actionability
75 mutations representing 40% of patients may be testable within clinical trials 5, but most alterations remain investigational. The most common potentially actionable pathways include:
- PI3K/AKT/mTOR pathway (PTEN, PIK3CA, TSC1/2, mTOR) 5
- Cell cycle (TP53, CDKN2A/B, RB1) 5, 6
- Rare targetable fusions (ETV6-NTRK3, FUS-TFCP2) 4
Ewing Sarcoma Specific
Molecular confirmation of EWSR1 gene rearrangement is mandated for Ewing sarcoma, either by FISH or identification of specific FET::ETS fusion via RNA panels 8. This also diagnoses other rare round cell sarcomas (CIC-rearranged, BCOR-altered) 8.
Avoid Repeat Testing
Longitudinal targeted DNA sequencing has limited value in translocation-associated sarcomas: only 27% acquire oncogenic alterations on repeat testing, and none are typically actionable for sarcomas specifically 10. Reserve repeat testing for specific clinical scenarios rather than routine surveillance.